High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$12.5M
$12,471,867
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Horich William Todd
• Officer • SVP, Commercial Operations
Discretionary Sell
2026-03-10
$244,145
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Commercial Operations
Discretionary Sell
|
2026-03-10 | $244,145 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Discretionary Sell
2026-03-09
$87,074
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Discretionary Sell
|
2026-03-09 | $87,074 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Horich William Todd
• Officer • SVP, Commercial Operations
Discretionary SellΔOwn -50.0%
2026-03-09
$239,652
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Commercial Operations
Discretionary SellΔOwn -50.0%
|
2026-03-09 | $239,652 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
GEMAYEL GEORGES
• Director
Discretionary SellΔOwn -24.4%
2026-03-06
$465,711
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Discretionary SellΔOwn -24.4%
|
2026-03-06 | $465,711 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Other
|
2026-03-06 | $199,996 | M | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
GEMAYEL GEORGES
• Director
Discretionary SellΔOwn -26.2%
2026-03-05
$537,100
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Discretionary SellΔOwn -26.2%
|
2026-03-05 | $537,100 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Other
|
2026-02-23 | $194,700 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-02-19 | $167,038 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Sensenig Bethany
• Director
10b5-1 SellΔOwn -27.2%
2026-02-19
$61,227
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 SellΔOwn -27.2%
|
2026-02-19 | $61,227 | S | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Hudson Frederick M.
• Director
Equity Compensation
2026-01-09
$0
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Equity Compensation
|
2026-01-09 | $0 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Other
|
2026-01-09 | $194,700 | M | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Equity Compensation
2025-12-19
$0
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Equity Compensation
|
2025-12-19 | $0 | M | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Equity Compensation
2025-12-19
$0
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Equity Compensation
|
2025-12-19 | $0 | M | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -49.2%
2025-12-19
$757,050
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -49.2%
|
2025-12-19 | $757,050 | S | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Other
2025-12-19
$379,500
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Other
|
2025-12-19 | $379,500 | M | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -24.4%
2025-12-19
$251,100
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -24.4%
|
2025-12-19 | $251,100 | S | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Other
2025-12-19
$197,000
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Other
|
2025-12-19 | $197,000 | M | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
Equity Compensation
2025-12-18
$0
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
Equity Compensation
|
2025-12-18 | $0 | M | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
Sell to Cover
2025-12-18
$31,552
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
Sell to Cover
|
2025-12-18 | $31,552 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Other
|
2025-11-21 | $194,700 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-09 | $2,950,654Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-09 | $78,682 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-10-09 | $2,055,625Large | M | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
NEWHALL CHARLES W III
• Director
10b5-1 Sell
2025-10-09
$61,860
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-10-09 | $61,860 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
NEWHALL CHARLES W III
• Director
10b5-1 SellΔOwn -18.4%
2025-10-09
$1,207,374Large
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 SellΔOwn -18.4%
|
2025-10-09 | $1,207,374Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-02 | $91,506 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-10-02 | $57,355 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-10-01 | $1,360,760Large | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-01 | $1,931,116Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-09-30 | $291,203 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-30 | $414,371 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-29 | $491,485 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-09-29 | $346,306 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-23 | $1,393,899Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-09-23 | $622,261 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-09-22 | $351,239 | M | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-22 | $779,921 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Discretionary SellΔOwn -24.4%
2025-09-12
$229,350
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Discretionary SellΔOwn -24.4%
|
2025-09-12 | $229,350 | S | Form 4 |
|
SUPN
M
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Other
2025-09-12
$197,000
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Other
|
2025-09-12 | $197,000 | M | Form 4 |